NCT01450384View on ClinicalTrials.gov

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

September 30, 2015

Conditions
Unspecified Adult Solid Tumor
Interventions
DRUG

sorafenib tosylate

Given PO

DRUG

pemetrexed disodium

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

biopsy

Optional correlative studies

Trial Locations (1)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT01450384 - Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter